Jeremy Tey1, Yu Yang Soon2, Timothy Cheo2, Kiat Huat Ooi2, Francis Ho2, Balamurugan Vellayappan2, David Chia2, Bee Choo Tai3. 1. Department of Radiation Oncology, National University Hospital, National Cancer Institute of Singapore, Singapore, Singapore Jeremy_tey@nuhs.edu.sg. 2. Department of Radiation Oncology, National University Hospital, National Cancer Institute of Singapore, Singapore, Singapore. 3. Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
Abstract
BACKGROUND/AIM: The aim of this study was to review the outcomes of palliative radiotherapy (RT) for hematuria treated with modern RT techniques. PATIENTS AND METHODS: This was a retrospective cohort study. The primary endpoint was symptom response rate. Secondary endpoints included symptom recurrence rate, overall survival and treatment-related toxicity. RESULTS: Median age was 82 years (range=36-98 years). Median biologically effective dose (BED) was 36 Gy. Sixty-seven percent of patients (39/58) responded to RT. The median survival duration was 5.6 months (range=0.02-47.6 months). One third (13/39) of responders had recurrence of hematuria. Competing Risk regression with death as the competing risk showed that patients treated with low BED regimen (<36 Gy) had 5.76 times the hazard of recurrence compared to high BED regimen (>36 Gy) (p=0.01). One patient (2%) developed grade 3 nausea and vomiting which required admission for intravenous hydration. CONCLUSION: BED regimens should be recommended as they are associated with a significantly lower rate of recurrent hematuria. Copyright
BACKGROUND/AIM: The aim of this study was to review the outcomes of palliative radiotherapy (RT) for hematuria treated with modern RT techniques. PATIENTS AND METHODS: This was a retrospective cohort study. The primary endpoint was symptom response rate. Secondary endpoints included symptom recurrence rate, overall survival and treatment-related toxicity. RESULTS: Median age was 82 years (range=36-98 years). Median biologically effective dose (BED) was 36 Gy. Sixty-seven percent of patients (39/58) responded to RT. The median survival duration was 5.6 months (range=0.02-47.6 months). One third (13/39) of responders had recurrence of hematuria. Competing Risk regression with death as the competing risk showed that patients treated with low BED regimen (<36 Gy) had 5.76 times the hazard of recurrence compared to high BED regimen (>36 Gy) (p=0.01). One patient (2%) developed grade 3 nausea and vomiting which required admission for intravenous hydration. CONCLUSION: BED regimens should be recommended as they are associated with a significantly lower rate of recurrent hematuria. Copyright
Authors: Danielle A Southern; Peter D Faris; Rollin Brant; P Diane Galbraith; Colleen M Norris; Merril L Knudtson; William A Ghali Journal: J Clin Epidemiol Date: 2006-10 Impact factor: 6.437
Authors: O M Salazar; P Rubin; F R Hendrickson; R Komaki; C Poulter; J Newall; S O Asbell; M Mohiuddin; J Van Ess Journal: Cancer Date: 1986-07-01 Impact factor: 6.860
Authors: G M Duchesne; J J Bolger; G O Griffiths; J Trevor Roberts; J D Graham; P J Hoskin; S D Fossâ; B M Uscinska; M K Parmar Journal: Int J Radiat Oncol Biol Phys Date: 2000-05-01 Impact factor: 7.038
Authors: Jeremy Tey; Bok Ai Choo; Cheng Nang Leong; En Yun Loy; Lea Choung Wong; Keith Lim; Jiade Jay Lu; Wee Yao Koh Journal: Medicine (Baltimore) Date: 2014-11 Impact factor: 1.889
Authors: Jeremy Tey; Yu Yang Soon; Wee Yao Koh; Cheng Nang Leong; Bok Ai Choo; Francis Ho; Balamurugan Vellayappan; Keith Lim; Ivan Wk Tham Journal: Oncotarget Date: 2017-04-11